Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist [Phase 2]

View source ↗

Summary

Phase 2 study evaluating NG101 in adults receiving a GLP-1 agonist has completed enrollment and aims to assess safety and efficacy in overweight/obese individua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NG101

Snippet

Sponsor: Neurogastrx, Inc. | Conditions: Overweight and Obesity, Healthy | Phase 2 | Status: COMPLETED